Tag: MGC026
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
Bristol Myers Squibb Enters Licensing Deal with Lonza for SYNtecan™ ADC...
Lonza, a global leader in contract development and manufacturing, has announced an exclusive single-target licensing agreement with Bristol Myers Squibb (BMS) for its proprietary SYNtecan™ linker-payload platform*. This agreement marks a significant milestone in advancing next-generation antibody-drug conjugate (ADC) therapeutics for oncology and other serious diseases.
